IQAI
NEUTRALImaging Biometrics Limited Announces Name Change
The healthcare technology company has formally changed its name from IQ-AI Ltd to Imaging Biometrics Ltd.
Imaging Biometrics Ltd.
0.8250GBX
0.00%
Market Cap
2.04M
Volume
3.05k
0% of avg
P/E Ratio
EPS (TTM)
Beta
2.6
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p0.8250p2.1000p
0.8250p
Upcoming Events
30 September 2026
Deadline for approval of rare pediatric disease designated drug to receive priority review voucher
High Impact Event
IQAI
GOODIQ-AI Applies for FDA Breakthrough Therapy Designation for Oral Gallium Maltolate Therapy
The healthcare company has applied for FDA Breakthrough Therapy Designation for its oral gallium maltolate therapy, a potential treatment for recurrent or refractory glioblastoma.
IQAI
NEUTRALIQ-AI Provides Notice of Annual General Meeting
The healthcare technology company has announced it will hold its Annual General Meeting on 22nd May 2025.
IQAI
GOODIQ-AI Limited Reports Improved Financial Results for 2024
The healthcare technology company reported strong revenue growth and significantly reduced losses in 2024, with the addition of a major new sales partner and a post-year end fundraise.
IQAI
NEUTRALIQ-AI Provides Update on Promising Phase 1 Study of Oral Gallium Maltolate
The healthcare company reports promising preliminary data from an ongoing Phase 1 study of an oral treatment for recurrent glioblastoma patients.
IQAI
BADIQ-AI Raises £250,000 Through Discounted Placing
The healthcare technology company has raised £250,000 through a discounted placing, potentially signaling low investor appetite and ongoing funding challenges.
IQAI
GOODIQ-AI Unveils AI-Powered Imaging Solutions, Advances Glioblastoma Drug Trial
Healthcare technology firm unveils AI-powered imaging solutions and advances glioblastoma drug trial
IQAI
GOODIQ-AI Appoints Brain Tumor Expert to Board of Directors
The healthcare company has appointed a renowned brain tumor expert to its board, aiming to bolster its expertise and networks in this area as it develops new treatments and imaging solutions.
IQAI
GOODIQ-AI Reports Revenue Growth and New Patent Filing
The healthcare company has filed a new patent application and reported strong revenue growth, driven by software sales. The firm is also making progress on a clinical trial and seeking funding for the next phase.
IQAI
NEUTRALBraveheart Investment Group Acquires 29.51% Stake in IQ-AI Limited
The healthcare technology company has reported that investment firm Braveheart Investment Group plc has acquired a 29.51% stake.